Prognostic Role of β-catenin/PTEN Expressions and Braf/Kras Mutations in Papillary Thyroid Carcinoma: Correlation with Response to Radioactive Iodine Therapy | ||||
| SECI Oncology Journal | ||||
| Volume 12, Issue 2, April 2024, Page 191-205 | ||||
 View on SCiNiTO | ||||
| Abstract | ||||
| Background: Papillary thyroid carcinoma (PTC) is the most common endocrine cancer; nevertheless, despite a favorable prognosis, some PTCs demonstrate aggressive behavior and are refractory to radioactive iodine therapy (RAIT). The study aims to evaluate the association between PTEN/β-catenin expression as well as BRAF/KRAS mutations on the pathological features and responsiveness to RAIT. Methods: A retrospective study included 52 cases of PTC. β-catenin and PTEN expressions were evaluated by immunohistochemistry. BRAFV600 and KRAS mutations were evaluated using PCR technique. All patients underwent thyroidectomy followed by RAIT, and at least 12 months of follow-up following initial therapy. Results: The study included 52 patients (38 females and 14 males, mean age: 42.07±14.17 years). Lost β-catenin membranous expression was significantly associated with nodal metastasis (P=0.011), lymphovascular invasion (P=0.041), and higher cumulative doses of RAI (P=0.0.034). Positive β-catenin cytoplasmic expression was significantly linked to persistent/recurrent structural disease (P=0.007). Negative PTEN cytoplasmic expression was significantly associated with advanced TNM staging (P=0.022), thyroid capsular infiltration, and extrathyroidal extension (P=0.005 and 0.008, respectively). There was no significant relationship found between PTCs harboring BRAFV600E mutation and pathological characteristics or responsiveness to RAI (P=0.521). Conclusions: Our results demonstrate that PTCs lacking membranous and expressing cytoplasmic β-catenin are significantly linked to more aggressive pathology, greater RAI dosages, and disease recurrence/persistence. Negative PTEN expression is substantially associated with advanced TNM staging and pathological characteristics. Furthermore, our data suggest that a positive BRAF mutation has no significant impact on RAIT efficacy in PTC patients without known distant metastases. | ||||
| Keywords | ||||
| Papillary thyroid carcinoma; Radioiodine therapy; PTEN; β-catenin; BRAFV600E; and KRAS mutation | ||||
|
Supplementary Files
|
||||
|
Statistics Article View: 20 |
||||
